Coya Therapeutics CEO on ALS urgency and fast-tracking COYA 302 for patient impact
As CEO of Coya Therapeutics, Dr Arun Swaminathan is steering the company’s lead programme, COYA 302, an immune-modulating combination designed…
10 Jun 2026
Dangerous waters: Geopolitics, supply chains and access to medicines
Shortages of medicines for conditions such as diabetes, attention deficit hyperactivity disorder (ADHD) and hormone replacement therapy (HRT) have long been a feature of the healthcare landscape, but recent events…
09 Jun 2026
Novo Nordisk puts AI at the centre of its clinical strategy
In the last few years, pharma leaders have been scrambling to see how artificial intelligence (AI) can augment every aspect of their business to increase output, accelerate timelines, and slash…
09 Jun 2026
Shift in biosimilar commercial landscape essential for sector sustainability, expert says
As the pharmacological treatment landscape continues to evolve, biologics are becoming increasingly incorporated into therapeutic regimens across a broad range of disease areas. When these branded drugs lose their patent…
05 Jun 2026
ASCO26 Podcast: an analyst rundown of the best readouts and key trends
While the 2026 American Society of Clinical Oncology (ASCO) conference may be over for another year, the editorial team at Pharmaceutical Technology are still buzzing from all the potentially paradigm-changing…
29 May 2026
Psychedelic-assisted therapies get a boost, but systems struggle to play catch-up
Following decades of stagnant research, psychedelic-assisted therapy has been heralded as a potentially transformative approach amid a global mental health crisis. According to World Health Organization (WHO) data published in…
28 May 2026
Validation to velocity: Japan’s pharma model comes under execution pressure
Japan’s pharmaceutical industry - the world’s third largest by market value after the United States and China - has long been associated with methodical development cycles and rigorous technical validation.…